Andrew Oakley

Andrew J.
Oakley is currently Director at Virometix AG, Executive Director at Novaremed AG, Director at Brian Oakley Ltd. since 2003, Director at Oakley Coachbuilders Ltd. since 2014, Director at UNION Therapeutics A, Director at Metys Pharmaceuticals AG, Independent Director at Tribeca Strategic Acquisition Corp.
starting 2026, and Member of The Institute of Chartered Accountants in Australia since 1987.
Former roles include Non-Executive Chairman at Onconetix, Inc. from 2025 to 2026, CFO, Secretary & Executive Director at Vectura Group Ltd. from 2015 to 2016, Chief Financial Officer, Secretary & Director at Vectura GmbH, Chief Financial Officer & Executive Vice President at Actelion Ltd., Chief Financial Officer & Executive Vice President at Nxera Pharma Co., Ltd. from 2017 to 2018, Chief Financial Officer at NovImmune SA in 2014, Member-Supervisory Board at Ventaleon GmbH, Chief Financial Officer & Executive Vice President at Actelion Pharmaceuticals Ltd. from 2003 to 2013, and Chief Financial Officer & Executive Vice President at Autolus Therapeutics Plc from 2018 to 2023.
Education includes undergraduate studies at Macquarie University and an MBA from London Business School.